QNCX
NASDAQQuince Therapeutics Inc.
News · 26 weeks40+100%
2025-11-022026-04-26
Mix1690d
- SEC Filings12(75%)
- Other4(25%)
Latest news
25 items- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form DEFA14A filed by Quince Therapeutics Inc.DEFA14A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form DEF 14A filed by Quince Therapeutics Inc.DEF 14A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form PRE 14A filed by Quince Therapeutics Inc.PRE 14A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form S-8 filed by Quince Therapeutics Inc.S-8 - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form 10-K filed by Quince Therapeutics Inc.10-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form NT 10-K filed by Quince Therapeutics Inc.NT 10-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRQuince Therapeutics Settles Approximately $16.4 Million of DebtQuince Therapeutics, Inc. (NASDAQ:QNCX) today announced the successful settlement of the company's outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. This marks a material milestone for Quince as the completion of the settlement resolves critical debt obligations and allows the company to advance its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Effective immediately upon the $5.5 million payment, Quince settled outstanding EIB debt obligations of approximately $16.4 million as of March 27, 2026. As a direct result of this $5.5 million payment, all of the company's obligations under
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.SCHEDULE 13G - Quince Therapeutics, Inc. (0001662774) (Subject)
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRQuince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic AlternativesQuince Therapeutics, Inc. (NASDAQ:QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions. LifeSci Capital will also act as the company's financial advisor in connection with any restructuring of the company's liabilities. The company does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has appr
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- ANALYSTQuince Therapeutics downgraded by Citizens JMPCitizens JMP downgraded Quince Therapeutics from Mkt Outperform to Mkt Perform
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRQuince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-TelangiectasiaPrimary and key secondary endpoint did not achieve statistical significance eDSP was generally well tolerated with no clinically meaningful safety concerns identified Company to cease clinical development of eDSP; Intends to preserve cash and explore available options Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T). In the NEAT study, th
- PRQuince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual MeetingQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association 2026 Annual Meeting taking place in Glasgow, Scotland January 28-30, 2026. The objective of the data analysis was to describe the safety profile of long-term use of the company's lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in children with A-T who received eDSP for a minimum of two years. Key highlights re
- INSIDERSEC Form 4 filed by CEO and CMO Thye Dirk4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
- INSIDERSEC Form 4 filed by President Ryan Charles S.4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
- INSIDERSEC Form 4 filed by CBO, COO & CCO Hannah Brendan4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
- INSIDERSEC Form 4 filed by Director Senner Christopher J.4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcloughlin Margaret4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
QNCX FAQ
6 questionsWhere does QNCX stock trade?
Quince Therapeutics Inc. (QNCX) is listed on NASDAQ.What sector and industry is QNCX in?
Quince Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Quince Therapeutics Inc. go public?
Quince Therapeutics Inc. (QNCX) completed its IPO in 2019.What are analysts saying about QNCX?
Quince Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Citizens JMP: Mkt Perform on 2026-01-30. Recent price targets range from $900.00 to $1000.00.What companies are similar to QNCX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare QNCX side-by-side with any of them on Quantisnow.How can I track QNCX on Quantisnow?
Quantisnow aggregates Quince Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QNCX to receive live email and push alerts on every new disclosure.